Clinical Trials

Clinical Trials - Lung Cancer Program at UCLA - Los Angeles, California

Immunotherapy / Dendritic Cell Therapy Trials:

1. A phase I trial of chemokine gene (CCL-21) modified dendritic cells in non-small cell lung cancer
   a. Eligibility - Patients with non-small cell lung cancer, Stage IIIB or Stage IV.
   b. Treatment - All patients receive two doses of their own (autologous) dendritic cells modified to express the chemokine by bronchoscopic or radiologic guided injections.
   c. Principal Investigator - Jay M. Lee, MD
   d. Contact - Fran Rosen
2. Michael Roth, MD trial.

Lung Cancer Chemoprevention Trials:

1. http://lungcancerprevention.com/Home.html
2. Celebrex for the prevention of lung cancer in ex-smokers.
3. Iloprost for the prevention of lung cancer in high risk patients.

Chemotherapy and Targeted Therapy Trials:

1. ATLAS
   a. Eligibility - Patients with non-small cell lung cancer, Stage IV or Stage IIIB with pleural effusion.
   b. Treatment - All patients receive four cycles of chemotherapy containing carboplatinum and an additional chemotherapeutic drug (paclitaxel, docetaxel, or gemcitabine). Patients with responses or stable disease are then randomized to receive maintenance bevacizumab or maintainance bevacizumab plus erlotinib.
   c. Primary Investigator - Fairooz F. Kabbinavar, MD
   d. Contact -
2. OSI-774-203
   a. Eligibility - Patients with non-small cell lung cancer, Stage IV or Stage IIIB with pleural effusion.
   b. Treatment - All patients receive erlotinib. Patients are randomized to receive erlotinib. plus chemotherapy (carboplatin and paclitaxel) or erlotinib alone.
   c. Primary Investigator - Fairooz F. Kabbinavar, MD
   d. Contact -
3. BRIDGE
   a. Eligibility - Patients with squamous cell lung cancer, Stage IV or IIIB with pleural effusion.
   b. Treatment - Patients will receive two cycles of carboplatinum and paclitaxel. Then, bevacizumab will be added to the carboplatinum and paclitaxel for cycles 3-6.
   c. Primary Investigator - Edward Garon, MD
   d. Contact -
4. PASSPORT
   a. Eligibility - Patients with non-squamous, non-small cell lung cancer who have brain metastases that have been treated with surgery and or radiation.
   b. Treatment - Patients will be treated with a carboplatinum and an additional chemotherapeutic drug (paclitaxel, docetaxel, or gemcitabine) plus bevacizumab if they have never received chemotherapy for metastatic disease. If they have received chemotherapy for metastatic disease they will receive bevacizumab plus docetaxel or pemetrexed or erlotinib.
   c. Primary Investigator - Fairooz F. Kabbinavar, MD
   d. Contact -
5. ZD6474
   a. Eligibility - Patients with non-small cell lung cancer who have developed progressive disease during chemotherapy or recurrent disease after chemotherapy.
   b. Treatment - All patients will be treated with docetaxel. In addition, half of the patients will be randomly assigned to receive ZD6474.
   c. Primary Investigator - Fairooz F. Kabbinavar, MD
   d. Contact
6. Erlotinib/Fulvestrant
   a. Eligibility - Patients with non-small cell lung cancer who have recurrent or progressive disease after two or more prior chemotherapy regimens.
   b. Treatment - All patients will receive erlotinib, with two thirds of the patients being randomized to receive fulvestrant in addition.
   c. Primary Investigator - Edward Garon, MD
   d. Contact -